RxDoctor Payments Data

Sandeep Rana, MD

Clinical Neurophysiology · Pittsburgh, PANPI 1871594283

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 72.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $10,777 and has fallen 97.5% since, to $267 in 2025.

$29,588in general payments, 2019–2025

Across 64 payments — averaging $462.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$21K
  • CSL Behring$8K
  • Biogen$197
  • AbbVie$186
  • Argenx US, Inc.$54
  • Avanir Pharmaceuticals, Inc.$53
  • plus $83 from 4 others
$279,187in research payments, 2019–2025

Across 96 payments — averaging $2908.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mitsubishi Tanabe Pharma Development America, Inc.$116K
  • Orion Corporation$87K
  • AstraZeneca$45K
  • Mallinckrodt Enterprises LLC$17K
  • Tanabe Pharma America, Inc.$9K
  • Mallinckrodt Hospital Products Inc.$5K

What the payments were for

  • Consulting fees$8,82030%
  • Speaking & faculty fees$17,07058%
  • Travel & lodging$2,0847%
  • Food & beverage$1,5185%
  • Education$950%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$81,762
Medicare patients
300
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone127$1,798,650
FirdapseAmifampridine Phosphate12$680,906
UltomirisRavulizumab-Cwvz14$529,357
RelyvrioSod Phenylbutyrat/Taurursodiol23$303,347
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$153,579
TeglutikRiluzole18$68,648
NuedextaDextromethorphan Hbr/Quinidine24$61,154
Pyridostigmine Bromide ErPyridostigmine Bromide13$24,519
Riluzole148$23,995
Pyridostigmine Bromide122$6,288
Oxcarbazepine13$2,411
Gabapentin105$2,368
Mycophenolate Mofetil28$2,312
Pregabalin23$1,005
Carbidopa-Levodopa ErCarbidopa/Levodopa14$916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$21,324$529,35714 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$27$153,57911 claims
Avanir Pharmaceuticals, Inc.Nuedexta$53$61,15424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →